Nektar Therapeutics NKTR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 100%+31.2pp | 68.8%+6.3pp | 62.5%-14.0pp | 76.5%+0.9pp | |
| Operating margin | -253.7%— | —— | -292.6%+116pp | -408.6%+29.1pp | |
| Net margin | -297.1%-169pp | -128.2%+178pp | -306.3%+93.7pp | -400%+114pp | |
| Returns | |||||
| Return on equity | -217.9%-86.3pp | -131.7%-20.7pp | -110.9%-40.6pp | -70.4%-10.8pp | |
| Return on invested capital | -86%-23.8pp | -62.2%+11.0pp | -73.2%-15.8pp | -57.4%-13.7pp | |
| Efficiency | |||||
| Asset turnover | 0.2×-0.1× | 0.3×+0.1× | 0.2×+0.1× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 5×+0.7× | 4.3×-2.2× | 6.5×-1.6× | 8×-1.3× | |
| Leverage | |||||
| Debt-to-equity | 1×-0.7× | 1.7×+0.8× | 0.9×+0.5× | 0.4×+0.1× | |
| Per Share | |||||
| Book value per share | $5.32+20.2% | $4.43+543% | $0.69-64.8% | $1.96-47.2% | |
| Valuation | |||||
| Market capitalization | $860.04M+401% | $171.55M+58.9% | $107.94M-74.6% | $424.78M-83.0% | |
| Price / sales | 15.6×+13.8× | 1.7×+0.5× | 1.2×-3.4× | 4.6×-19.9× | |
| Price / book | 9.6×+6.7× | 2.8×+2.0× | 0.8×-0.3× | 1.2×-2.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Nektar Therapeutics (NKTR) runs a 100.0% gross margin and a -242.0% operating margin, with a -284.2% net margin.
- Where do Nektar Therapeutics's ratios come from?
- Every ratio is computed from Nektar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
